Related Experiment Video
Updated: Aug 14, 2025
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.9K
Tardive Dyskinesia Following Low-Dose Risperidone
Ahmad E Rokon1,2, Faisal A Alsomali1,2, Malek A Alrasheed1,2
1College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Cureus
|January 11, 2023
Summary
Tardive dyskinesia can occur with low-dose second-generation antipsychotics, even in patients with underlying conditions. This case highlights the need for further research into atypical antipsychotic-induced movement disorders.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Tardive dyskinesia (TD) is a movement disorder often linked to long-term neuroleptic use.
- It typically arises from dopamine receptor-blocking agents, primarily first-generation antipsychotics or high-dose second-generation antipsychotics (SGAs).
Observation:
- A 28-year-old female with osteogenesis imperfecta and major depressive disorder with psychotic features developed TD.
- She received a low-dose (2 mg) of risperidone, an SGA, for psychosis over three months.
- Symptoms included akathisia, dystonia, and involuntary movements, persisting over eight weeks after medication cessation.
Findings:
- The patient was diagnosed with tardive dyskinesia despite low-dose SGA use and a pre-existing condition.
- This case suggests potential contributing factors beyond typical risk profiles for TD development.
Implications:
- Further research is crucial to identify novel risk factors for tardive dyskinesia.
- Understanding the mechanisms by which SGAs contribute to TD is essential for patient safety and treatment strategies.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
333
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
333
01:15REM Sleep Behavior Disorder
331
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
331
01:21Antipsychotic Drugs: Typical and Atypical Agents
286
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
286
01:20Antiepileptic Drugs: Potassium Channel Activators
240
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
240
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
333
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
333
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
496
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
496